The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
Open accessAbstract
BACKGROUND: The programmed death receptor 1 (PD-1) protein is a cell-surface receptor on certain lymphocytes that, with its ligand programmed death ligand 1 (PD-L1), helps to down-regulate immune responses. Many cancer types express PD-L1 and evade immune recognition via the PD-1/PD-L1 interaction. Precision therapies targeting the PD-1/PD-L1 pathway have the potential to improve response and thereby offer a novel treatment avenue to some patients with cancer. However, this new therapeutic approach requires reliable methods for identifying patients whose cancers are particularly likely to respond. Therefore, we conducted a systematic literature review assessing evidence on test validation and scoring algorithms for PD-L1 immunohistochemistry (IHC) tests that might be used to select potentially responsive patients with bladder/urothelial cell, lung, gastric, or ovarian cancers for immunotherapy treatment. METHODS AND RESULTS: To identify evidence on commercially available PD-L1 IHC assays, we systematically searched MEDLINE and Embase for relevant studies published between January 2010 and September 2016 and appraised abstracts from recent oncology conferences (January 2013 to November 2016). Publications that met the predefined inclusion criteria were extracted and key trends summarized. In total, 26 eligible primary studies were identified, all of which reported on the test validation metrics associated with PD-L1 IHC tests in lung cancer, most using immunohistochemistry testing. There was significant heterogeneity among the available tests for PD-L1. Specifically, no definitive cutoff for PD-L1 positivity was identifiable, with more than one threshold being reported for most antibodies. Studies also differed as to whether they evaluated tumor cells only or tumor cells and tumor-infiltrating immune cells. However, all of the tests developed and validated to support a therapeutic drug in the context of phase 2-3 clinical trials reported more than 90% inter-reader concordance. In contrast, other PD-L1 antibodies identified in the literature reported poorer concordance. CONCLUSIONS: Published validation metric data for PD-L1 tests are mainly focused on immunohistochemistry tests from studies in lung cancer. The variability in test cutoffs and standards for PD-L1 testing suggests that there is presently no standardized approach. This current variability may have implications for the uptake of precision treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“It has also been theorized that different cell phenotypes/characteristics may also contribute to this variability in PD-L1 expression across cancer cells [32].”
BackgroundFehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer
Phillips, T., Simmons, P., Inzunza, H. D., Cogswell, J., Novotny, J., Taylor, C., & Zhang, X. (2015) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000256 · Cited by 189 · cited 3×
“28–8 (Dako) [nivolumab] 1%: 3 studies [7, 10, 12] 5%: 2 studies [10, 11] 10%: 1 study [10] 50%: 1 study [11]”
Background
Research works printed but not linked: 31
- Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K, et al. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology. 2016;69(2):177–86. · DOI
- Boyd ZS, Smith D, Baker B, Vennapusa B, Koeppen H, Kowanetz M, et al. Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab. In: The inaugural international cancer immunotherapy conference; September 16–19, 2015; New York, NY [abstract B001]. · DOI
- Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol. 2016;24(6):392–7. · DOI · Paper page
- Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 2016;29(10):1165–72. · DOI · Paper page
- Anderson SM, Zhang L, Brailey L. Evaluation of two immunohistochemical assays for PD-L1 expression. J Clin Oncol 2016;34(suppl) [abstract e23220]. · DOI
- Gaule PB, Rehman J, Smithy JW, Toki MI, Han G, Neumeister V, et al. Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer. J Clin Oncol. 2016;34(suppl) [abstract 9040]. · doi:10.1200/jco.2016.34.15_suppl.9040
- Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468(5):511–25. · DOI · Paper page
- Rivalland G, Ameratunga M, Asadi K, Walkiewicz M, Knight S, John T, et al. Programmed death–ligand 1 (PD-L1) immumohistochemistry in NSCLC: comparison and correlation between two antibodies. J Clin Oncol. 2016;34(suppl) [abstract e20036]. · doi:10.1200/jco.2016.34.15_suppl.e20036
- Schildhaus HU, Richardt P, Wilsberg L, Schmitz K. Occurrence of PDL1/2 copy number gains detected by FISH in adeno and squamous cell carcinomas of the lung and association with PDL1 overexpression in adenocarcinomas. J Clin Oncol. 2016;34(suppl) [abstract 3031]. · doi:10.1200/jco.2016.34.15_suppl.3031
- Ilie M, Falk AT, Butori C, Chamorey E, Bonnetaud C, Long E, et al. PD-L1 expression in basaloid squamous cell lung carcinoma: relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. Mod Pathol 2016;29(12):1552–1564. · DOI
- Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol. 2016;11(1):95. · DOI · Paper page
- Smith J, Robida MD, Acosta K, Vennapusa B, Mistry A, Martin G, et al. Quantitative and qualitative characterization of two PD-L1 clones: SP263 and E1L3N. Diagn Pathol 2016;11(1):44. · DOI
- Chaft JE, Chao B, Akerley WL, Gordon M, Antonia SJ, Callahan J, et al. Evaluation of PD-L1 expression in metachronous tumor samples and FDG-PET as a predictive biomarker in Ph2 study (FIR) of atezolizumab (MPDL3280A). Oral presentation at: 16th World Conference on Lung Cancer; September 6–9, 2015; Denver, CO [ORAL 02.06].
- Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147–53. · DOI · Paper page
- Kowanetz M, Koeppen H, Boe M, Chaft JE, Rudin CM, Zou W, et al. Spatiotemporal effects on programmed death ligand 1 (PD-L1) expression and immunophenotype of non-small cell lung cancer (NSCLC). Oral presentation at: 16th World Conference on Lung Cancer; September 6–9, 2015; Denver, CO [ORAL 13.03].
- McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2016;2(1):46–54. · DOI · Paper page
- Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22(18):4585–93. · DOI · Paper page
- Huynh TG, Morales-Oyarvide V, Campo MJ, Gainor JF, Bozkurtlar E, Uruga H, et al. Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment. J Thorac Oncol. 2016;11(11):1869–78. · DOI
- Inamura K, et al. Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. Jpn J Clin Oncol. 2016;46(10):935–41. · DOI
- Inoue Y, Yoshimura K, Mori K, Kurabe N, Kahyo T, Mori H, et al. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. Oncotarget. 2016;7(22):32113–28. · DOI
- Mansfield AS, Murphy SJ, Peikert T, Yi ES, Vasmatzis G, Wigle DA, et al. Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res. 2016;22(9):2177–82. · DOI
- Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, et al. Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non–small-cell lung cancer. Clin Lung Cancer. 2015;16(5):385–90. · DOI
- Marti AM, Martinez P, Navarro A, Cedres S, Murtra-Garrell N, Salva F, et al. Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung. Presented at: American Society of Clinical Oncology Annual Meeting; May 30–June 03, 2014; Chicago, IL [abstract 7569]. · DOI
- Midha A, Sharpe A, Scott M, Walker J, Shi K, Ballas M, et al. PD-L1 expression in advanced NSCLC: primary lesions versus metastatic sites and impact of sample age. Presented at: American Society of Clinical Oncology Annual Meeting; June 3–7, 2016; Chicago, IL [abstract 3025]. · doi:10.1200/jco.2016.34.15_suppl.3025
- Casadevall D, Pijuan L, Clave S, Taus A, Hernandez A, Lorenzo M, et al. Evaluation of tumor- and stromal immune marker heterogeneity in lung adenocarcinoma. J Clin Oncol. 2016;34(suppl) [abstract e20029]. · doi:10.1200/jco.2016.34.15_suppl.e20029
- Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, et al. Cancer treatment with anti-PD-1/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? Drugs. 2016;76(9):925–45. · DOI
- Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9(1):47. · DOI · Paper page
- Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid response report: peer-reviewed summary with critical appraisal. Epidermal growth factor receptor mutation analysis in advanced non-small cell lung cancer: a review of the clinical effectiveness and guidelines. 2010. https://www.cadth.ca/media/pdf/M0017_EGFR_Testing_for_NSCLC_e.pdf . Accessed 11 May 2017.
- Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241–56. · DOI · Paper page
- Gupta R, Dastane AM, Jr MKR, Marchevsky AM. The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. Hum Pathol. 2009;40(3):356–65. · DOI
- Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, et al. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet. 2016;388(10048):1002–11. · DOI · Paper page
Cited by
He, S., Bhatt, R., Brown, C., Brown, E. A., Buhr, D. L., Chantranuvatana, K., Danaher, P., Dunaway, D., Garrison, R. G., Geiss, G., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01483-z · Cited by 814
Yin, S., & Yu, Y. (2022) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2022.132608 · Cited by 370
Liu, Y., Zugazagoitia, J., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1040 · Cited by 322
Translational AI and deep learning in diagnostic pathology
Serag, A., Ion-Margineanu, A., Qureshi, H., McMillan, R., Saint Martin, M.-J., Diamond, J., O'Reilly, P., & Hamilton, P. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00185 · Cited by 274
Checkpoint inhibitor immunotherapy in kidney cancer
Xu, W., Atkins, M. B., & McDermott, D. F. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0282-3 · Cited by 261
Metadata
- Authors
- Udall, M., Rizzo, M., Kenny, J., Doherty, J., Dahm, S., Robbins, P., & Faulkner, E.
- Venue
- Diagnostic Pathology
- Published
- 2018-02-09
- Volume
- 13
- Issue
- 1
- Pages
- 12-12
- ISSN
- 1746-1596 (ISSN-L)
- OpenAlex
- W2797182287
- Cited by
- 208
- References
- 4
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Pfizer Inc.
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. https://app.cochat.ai/papers/10.1186/s13000-018-0689-9
- The paper
- Udall, M., Rizzo, M., Kenny, J., Doherty, J., Dahm, S., Robbins, P., & Faulkner, E. (2018). PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagnostic Pathology. https://doi.org/10.1186/s13000-018-0689-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.